hot news

On January 31, 2023, the Shaanxi Provincial Youth and Middle-aged Head and Neck Tumor Immunotherapy Forum, organized by SXIMEA and hosted by the First Affiliated Hospital of Xi'an Jiao Tong University, was successfully held. The conference was chaired by Professor Rui Liu, Deputy Director of the Department of Radiation Oncology at the First Affiliated Hospital of Xi'an Jiao Tong University, with more than 300 medical professionals from the province participating in online learning.

Professor Tao Tian from the Department of Oncology at the First Affiliated Hospital of Xi'an Jiao Tong University shared a presentation titled "Exploration of Immunotherapy in Unresectable Locally Advanced Head and Neck Squamous Cell Carcinoma." From a multidisciplinary perspective, he discussed the important position and key role of immunotherapy in the treatment of unresectable locally advanced head and neck squamous cell carcinoma.

Professor Zang Jian from the Department of Radiation Oncology at the XiJing Hospital of Air Force Medical University shared a presentation titled "Exploration of Immunotherapy Combined with Radiotherapy for Locally Advanced Stages," introducing the important role of radiotherapy in the treatment of head and neck squamous cell carcinoma. He also conducted a data review and retrospective analysis of immunotherapy combined with radiotherapy and provided a future outlook.

Professor Honghui Li from the Department of Otorhinolaryngology Head and Neck Surgery at the First Affiliated Hospital of Xi'an Jiao Tong University shared a presentation titled "Pembrolizumab - Bringing New Treatment Modalities for R/M HNSCC Patients." He revisited the long-lasting benefits brought by pembrolizumab as a first-line monotherapy in the Keynote048 trial for patients with a PD-L1 CPS ≥20, offering the hope of prolonged survival for more patients.

Professor Ying Zan from the Department of Oncology at the Second Affiliated Hospital Of Xi'an Jiao Tong University shared a presentation titled "Management of Adverse Reactions in Immunotherapy." The standardized treatment of head and neck squamous cell carcinoma requires the participation of multiple disciplines. Proper management of adverse reactions is crucial for preserving function, eradicating tumors, and improving the quality of life for patients with head and neck squamous cell carcinoma. By sharing strategies for adverse reaction management, she aimed to provide comprehensive support and guidance for patients with head and neck squamous cell carcinoma.

The conference also invited Professor Yuan An from the Department of Head and Neck Surgery at Shaanxi Provincial Cancer Hospital, Professor Liang Li from the Department of Radiation Oncology, Professor Qu Yiping from the Department of Radiation Oncology at the First Affiliated Hospital of Xi'an Jiao Tong University, Professor Xuan Liang from the Department of Oncology, Professor Ting Liang from the Department of Radiology, Professor Hua Liang from the Department of Pathology, and Professor Qian Zhao from the Department of Otorhinolaryngology Head and Neck Surgery. The expert teams covered multiple hospitals and specialties, including surgery, oncology, pathology, radiology, and radiation oncology. The attendees engaged in lively exchanges and discussions on topics such as immunotherapy efficacy PR, considerations for subsequent treatments, adverse reaction management, and further clinical diagnosis and treatment. They reached a consensus on building a comprehensive, multi-level, and broad-based multidisciplinary treatment model. The conference fully demonstrated the commitment of the medical professionals to always putting patients first in the treatment of head and neck squamous cell carcinoma, aiming to provide them with longer survival opportunities, better treatment experiences, and a higher quality of life.